Clinical and demographic characteristics of patients receiving different oral hypoglycemic agents

Pharmacoepidemiology and Drug Safety

Volumn 18, Issue 8, 2009, Pages 756-760

  Gomes, Tara ^a   Juurlink, David N ^a,b,c,e   Lipscombe, Lorraine L ^a,d,e   Mamdani, Muhammad M ^a,c,e,f  

^a INSTITUTE FOR CLINICAL EVALUATIVE SCIENCES   (Canada)

^b SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d WOMEN S COLLEGE HOSPITAL   (Canada)

^e UNIVERSITY OF TORONTO   (Canada)

^f ST MICHAEL'S HOSPITAL   (Canada)

Author keywords

Diabetes; Oral hypoglycemic agents; Patient characteristics; Thiazolidinediones

Indexed keywords

ACARBOSE; METFORMIN; NATEGLINIDE; ORAL ANTIDIABETIC AGENT; PIOGLITAZONE; REPAGLINIDE; ROSIGLITAZONE; SULFONYLUREA; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT;

AGED; ARTICLE; CANADA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COMORBIDITY; CONTROLLED STUDY; DEMOGRAPHY; DIABETES MELLITUS; DRUG SAFETY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NURSING HOME PATIENT; PRIORITY JOURNAL; AGE; CHEMICALLY INDUCED DISORDER; COMPARATIVE STUDY; ORAL DRUG ADMINISTRATION; REGISTER; RISK ASSESSMENT; RISK FACTOR; SAFETY;

ADMINISTRATION, ORAL; AGE FACTORS; AGED; AGED, 80 AND OVER; CARDIOVASCULAR DISEASES; COMORBIDITY; CONSUMER PRODUCT SAFETY; DIABETES MELLITUS; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; ONTARIO; REGISTRIES; RISK ASSESSMENT; RISK FACTORS; THIAZOLIDINEDIONES;

EID: 70349780041     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.1750     Document Type: Article

References (16)

1. Gerrits CM, Bhattacharya M, Manthena S, Baran R, Perez A, Kupfer S. A comparison of pioglitazone and rosiglitazone for hospitalization for acute myocardial infarction in type 2 diabetes. Pharmacoepidemiol Drug Saf 2007; 16(10): 1065-1071. (Pubitemid 350020057)
2. Karter AJ, Ahmed AT, Liu J, Moffet HH, Parker MM. Pioglitazone initiation and subsequent hospitalization for congestive heart failure. Diabet Med 2005; 22(8): 986-993. (Pubitemid 41025993)
3. Lipscombe LL, Gomes T, Levesque LE, Hux JE, Juurlink DN, Alter DA. Thiazolidinediones and cardiovascular outcomes in older patients with diabetes. JAMA 2007; 298(22): 2634-2643. (Pubitemid 350254955)
4. Margolis DJ, Hoffstad O, Strom BL. Association between serious ischemic cardiac outcomes and medications used to treat diabetes. Pharmacoepidemiol Drug Saf 2008; 17(8): 753-759.
5. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007; 356(24): 2457-2471. (Pubitemid 46919772)
6. Singh S, Loke YK, Furberg CD. Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. JAMA 2007; 298(10): 1189-1195. (Pubitemid 47403105)
7. Koro CE, Fu Q, Stender M. An assessment of the effect of thiazolidinedione exposure on the risk of myocardial infarction in type 2 diabetic patients. Pharmacoepidemiol Drug Saf 2008; 17(10): 989-996.
8. Walker AM, Koro CE, Landon J. Coronary heart disease outcomes in patients receiving antidiabetic agents in the PharMetrics database 2000-2007. Pharmacoepidemiol Drug Saf 2008; 17(8): 760-768.
9. Hartung DM, Touchette DR, Bultemeier NC, Haxby DG. Risk of hospitalization for heart failure associated with thiazolidinedione therapy: a medicaid claims-based case-control study. Pharmacotherapy 2005; 25(10): 1329-1336.
10. GlaxoSmithKline responds to JAMA article on the ICES Thiazolidinediones and Cardiovascular Outcomes in Older Patients with Diabetes. http://www.gsk.com/media/press-kits/avandia-11dec2007.pdf Accessed 14 November 2008. Ref Type: Generic.
11. Hux JE, Ivis F, Flintoft V, Bica A. Diabetes in Ontario: determination of prevalence and incidence using a validated administrative data algorithm. Diabetes Care 2002; 25(3): 512-516. (Pubitemid 41103345)
12. Improving Health Care Data in Ontario. ICES Investigative Report. Toronto: Institute for Clinical Evaluative Sciences; 2005.
13. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992; 45(6): 613-619.
14. Schneeweiss S, Seeger JD, Maclure M, Wang PS, Avorn J, Glynn RJ. Performance of comorbidity scores to control for confounding in epidemiologic studies using claims data. Am J Epidemiol 2001; 154(9): 854-864. (Pubitemid 33000813)
15. Mamdani M, Sykora K, Li P, et al. Reader's guide to critical appraisal of cohort studies: 2. Assessing potential for confounding. Br Med J 2005; 330(7497): 960-962.
16. American Diabetes Association Standards of medical care in diabetes. Diabetes Care 2005; 28 (Suppl 1): S4-S36.